Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FTSV

Forty Seven (FTSV) Stock Price, News & Analysis

Forty Seven logo

About Forty Seven Stock (NASDAQ:FTSV)

Advanced Chart

Key Stats

Today's Range
$95.51
$95.51
50-Day Range
$95.51
$95.51
52-Week Range
$5.53
$95.51
Volume
N/A
Average Volume
1.61 million shs
Market Capitalization
$4.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FTSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forty Seven and its competitors with MarketBeat's FREE daily newsletter.

FTSV Stock News Headlines

Janus Henderson Forty D
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Janus Henderson Forty T
Janus Henderson Forty S
See More Headlines

FTSV Stock Analysis - Frequently Asked Questions

Forty Seven Inc (NASDAQ:FTSV) released its earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.38). The firm earned $15.68 million during the quarter, compared to analysts' expectations of $15.80 million.

Forty Seven (FTSV) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Forty Seven investors own include Gilead Sciences (GILD), TG Therapeutics (TGTX), Clovis Oncology (CLVS), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Abbott Laboratories (ABT) and ACADIA Pharmaceuticals (ACAD).

Company Calendar

Last Earnings
11/12/2019
Today
7/11/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FTSV
CIK
N/A
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$87.62 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-50.38%
Return on Assets
-44.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.81
Quick Ratio
14.81

Sales & Book Value

Annual Sales
$15.68 million
Price / Sales
293.33
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.52 per share
Price / Book
12.70

Miscellaneous

Outstanding Shares
48,156,000
Free Float
N/A
Market Cap
$4.60 billion
Optionable
Not Optionable
Beta
0.40
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:FTSV) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners